MRD Through a Broader Genomic Lens: Findings From A Retrospective Study of NGS-based MRD Analysis In AML Sample Cohorts

Thursday, January 28, 2027 at 2:40 PM to 3:10 PM · 30 min. (Europe/London)
Cancer Diagnostics Stage
Day 2 - Thursday 28th January
CancerDiagnosticsLiquid Biopsy

Information

1. Learn how detection of low-level residual leukemic cells can help develop a better understanding of relapse risk and impact treatment strategies.



2. Evaluate the potential of the SureSeq Myeloid MRD Plus Panel for MRD analysis compared to traditional technologies, including its sensitivity for broad biomarker ranges and complex variants like FLT3-ITDs.



3. Understand how ultrahigh-sensitivity NGS panels can be integrated into genomic workflows to generate comprehensive genomic profiles from AML research samples.



SureSeq: For Research Use Only. Not for Use in Diagnostic Procedures.